BioCentury
ARTICLE | Clinical News

EC approves Novartis' rituximab biosimilar Rixathon

August 11, 2017 4:07 PM UTC

In June, Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved Rixathon (GP2013), a biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY), for all of MabThera's...

BCIQ Company Profiles

Novartis AG

Roche